Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffuse large B-cell lymphoma

Next Previous
Trial Profile

A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffuse large B-cell lymphoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Obinutuzumab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 08 Dec 2020 Samples from this study (n=40) were used to assess the utility of ctDNA in high-risk patients with DLBCL, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
    • 15 Jul 2020 Status changed from active, no longer recruiting to completed.
    • 21 Jun 2020 Results assessing utility of ctDNA in identifying high-risk pts with DLBCL, presented at the 25th Congress of the European Haematology Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top